Search

Author/Creator Narasimhan, Narayana

1. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Issue 2 (9th July 2019)

Authors:
Tugnait, Meera; Gupta, Neeraj; Hanley, Michael J.; Sonnichsen, Daryl; Kerstein, David; Dorer, David J.; Venkatakrishnan, Karthik; Narasimhan, Narayana
Journal:
Clinical pharmacology in drug development
Issue:
Volume 9:Issue 2(2020)
Page Start:
214
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation. (24th May 2014)

Authors:
Stroh, Mark; Talaty, Jennifer; Sandhu, Punam; McCrea, Jacqueline; Patnaik, Amita; Tolcher, Anthony; Palcza, John; Orford, Keith; Breidinger, Sheila; Narasimhan, Narayana; Panebianco, Deborah; Lush, Richard; Papadopoulos, Kyriakos P.; Wagner, John A.; Trucksis, Michele; Agrawal, Nancy
Journal:
Journal of clinical pharmacology
Issue:
Volume 54:Number 11(2014:Nov.)
Page Start:
1256
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development. (16th December 2021)

Authors:
Hanley, Michael J.; Diderichsen, Paul M.; Narasimhan, Narayana; Srivastava, Shouryadeep; Gupta, Neeraj; Venkatakrishnan, Karthik
Journal:
Journal of clinical pharmacology
Issue:
Volume 62:Number 4(2022)
Page Start:
555
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗